UTHR Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
UTHR passed our risk checks.
United Therapeutics Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$323.08 |
52 Week High | US$343.98 |
52 Week Low | US$208.62 |
Beta | 0.56 |
11 Month Change | -1.56% |
3 Month Change | 17.80% |
1 Year Change | 41.63% |
33 Year Change | 60.70% |
5 Year Change | 289.96% |
Change since IPO | 5,201.83% |
Recent News & Updates
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04Recent updates
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Shareholder Returns
UTHR | US Biotechs | US Market | |
---|---|---|---|
7D | -2.4% | 2.7% | 4.0% |
1Y | 41.6% | 15.4% | 24.9% |
Return vs Industry: UTHR exceeded the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: UTHR exceeded the US Market which returned 21.7% over the past year.
Price Volatility
UTHR volatility | |
---|---|
UTHR Average Weekly Movement | 3.7% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: UTHR has not had significant price volatility in the past 3 months.
Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
UTHR fundamental statistics | |
---|---|
Market cap | US$14.41b |
Earnings (TTM) | US$1.07b |
Revenue (TTM) | US$2.62b |
13.4x
P/E Ratio5.5x
P/S RatioIs UTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UTHR income statement (TTM) | |
---|---|
Revenue | US$2.62b |
Cost of Revenue | US$291.80m |
Gross Profit | US$2.32b |
Other Expenses | US$1.26b |
Earnings | US$1.07b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 24.04 |
Gross Margin | 88.85% |
Net Profit Margin | 40.87% |
Debt/Equity Ratio | 8.8% |
How did UTHR perform over the long term?
See historical performance and comparison